Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus Sells 9,682 Shares

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 9,682 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at $1,552,445.92. This trade represents a 49.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Gail Boxer Marcus also recently made the following trade(s):

• On Thursday, November 14th, Gail Boxer Marcus sold 2,212 shares of Natera stock. The shares were sold at an average price of $158.53, for a total value of $350,668.36.

Natera Trading Down 3.3 %

NTRA traded down $5.60 on Friday, reaching $163.76. 354,674 shares of the company’s stock were exchanged, compared to its average volume of 1,342,488. The company has a market cap of $21.62 billion, a price-to-earnings ratio of -96.14 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a twelve month low of $53.62 and a twelve month high of $171.95. The company’s 50 day moving average is $129.84 and its 200-day moving average is $117.00.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same period last year, the business posted ($0.95) EPS. The company’s revenue was up 63.9% on a year-over-year basis. Equities analysts predict that Natera, Inc. will post -1.66 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Natera by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock worth $1,010,152,000 after purchasing an additional 72,848 shares during the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in Natera in the 1st quarter worth $220,000. Natixis acquired a new position in shares of Natera in the 1st quarter valued at $758,000. Magnetar Financial LLC grew its holdings in shares of Natera by 52.5% in the 1st quarter. Magnetar Financial LLC now owns 176,643 shares of the medical research company’s stock worth $16,156,000 after purchasing an additional 60,814 shares during the last quarter. Finally, Hood River Capital Management LLC acquired a new position in Natera in the first quarter worth $2,821,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on NTRA. Piper Sandler upped their target price on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday. The Goldman Sachs Group upped their price target on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Morgan Stanley lifted their price target on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Robert W. Baird raised their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Leerink Partners upped their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $140.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.